Ridinilazole

Last updated
Ridinilazole
Ridinilazole.svg
Clinical data
Other namesSMT19969
ATC code
  • None
Identifiers
  • 2,2'-Di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole)
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C24H16N6
Molar mass 388.434 g·mol−1
3D model (JSmol)
  • c6cc(c5nc4ccc(c3ccc2nc(c1ccncc1)[nH]c2c3)cc4[nH]5)ccn6

Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic under evaluation for oral administration for the treatment of Clostridioides difficile infection (CDI). In vitro, it demonstrates bactericidal activity against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell division. [1] It possesses desirable properties for the treatment of CDI, namely that it is a narrow-spectrum antibiotic which exhibits activity against C. difficile while having little impact on other normal intestinal flora and that it is only minimally absorbed systemically after oral administration. [2] When Ridinilazole was originally developed, there were only three antibiotics in use for treating CDI: vancomycin, fidaxomicin, and metronidazole. [1] [2] The recurrence rate of CDI is high, which has spurred research into other treatment options with the aimed reduce the rate of recurrence. [3] [4]

As of 2019, two phase II trials had been completed and two phase III trials comparing ridinilazole with vancomycin for CDI were anticipated to conclude in September 2021. [2] [5] [6] Ridinilazole was designated as a Qualified Infectious Disease Product (QIDP) and was granted Fast Track status by the U.S. FDA. [2] Fast Track status is reserved for drugs designed to treat diseases where there is currently a gap in the treatment, or a complete lack thereof. [7] The QIDP designation adds five more years of exclusivity for ridinazole upon approval. [8]

See also

References

  1. 1 2 Cho JC, Crotty MP, Pardo J (March 2019). "Clostridium difficile infection". Annals of Gastroenterology. 32 (2): 134–140. doi:10.20524/aog.2018.0336. PMC   6394264 . PMID   30837785.
  2. 1 2 3 4 Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW (April 2019). "Ridinilazole for the treatment of Clostridioides difficile infection". Expert Opinion on Investigational Drugs. 28 (4): 303–310. doi:10.1080/13543784.2019.1582640. PMID   30767587. S2CID   73422150.
  3. Bassères E, Endres BT, Dotson KM, Alam MJ, Garey KW (January 2017). "Novel antibiotics in development to treat Clostridium difficile infection". Current Opinion in Gastroenterology. 33 (1): 1–7. doi:10.1097/MOG.0000000000000332. PMID   28134686. S2CID   32454489. These tables highlight the increased drug development directed towards CDI due to the rise in prevalence of infections and to attempt to reduce the number of recurrent infections.
  4. Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH (August 2016). "Ridinilazole: a novel therapy for Clostridium difficile infection". International Journal of Antimicrobial Agents. 48 (2): 137–43. doi: 10.1016/j.ijantimicag.2016.04.026 . PMID   27283730. there exists a significant unmet and increasing medical need for new therapies to treat CDI, specifically those that can reduce the rate of disease recurrence.
  5. Clinical trial number NCT03595553 for "Ri-CoDIFy 1: Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection" at ClinicalTrials.gov
  6. Collins DA, Riley TV (September 2022). "Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile". Letters in Applied Microbiology. 75 (3): 526–536. doi:10.1111/lam.13664. PMC   9541751 . PMID   35119124.
  7. "Fast Track". U.S. Food and Drug Administration. 2018-11-03. Archived from the original on May 4, 2019.
  8. "HHS spurs new antibiotic development for biodefense and common infections". Public Health Emergency. U.S. Department of Health and Human Services. Retrieved 2020-12-04.